Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01009593 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
A Phase 3 study, sponsored by Abbott.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,035
- Enrollment target
NCT01009593 is a Phase 3 study that was terminated before completion, run by Abbott. The registered enrollment target is 1,035 participants.
The verdict
NCT01009593, a Phase 3 study, was terminated before completion, sponsored by Abbott.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,035 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the overall survival (OS) of oral linifanib given as monotherapy once daily (QD) compared to sorafenib given twice daily (BID) per standard of care in subjects with advanced or metastatic HCC.
Interventions
- DRUG Sorafenib
- DRUG ABT-869
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,035 participants |
| Start Date | 2010-01 |
| Est. Completion | 2012-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01009593
The ClinicalTrials.gov registry entry for NCT01009593 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,035 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sorafenib is the first listed.
NCT01009593 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01009593 about?
NCT01009593 is a clinical study titled "Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)". The primary objective of this study is to assess the overall survival (OS) of oral linifanib given as monotherapy once daily (QD) compared to sorafenib given twice daily (BID) per standard of care in subjects with advanced or metastatic HCC.
What is the current status of trial NCT01009593?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,035 participants. The study started on 2010-01. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01009593?
The interventions under investigation include: Sorafenib (DRUG), ABT-869 (DRUG).
Who is sponsoring clinical trial NCT01009593?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.